Your browser doesn't support javascript.
loading
Leveraging lessons learned from the COVID-19 pandemic for HIV.
Calder, Thomas; Tong, Tina; Hu, Dale J; Kim, Jerome H; Kotloff, Karen L; Koup, Richard A; Marovich, Mary A; McElrath, M Juliana; Read, Sarah W; Robb, Merlin L; Renzullo, Philip O; D'Souza, M Patricia.
Afiliación
  • Calder T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • Tong T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • Hu DJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • Kim JH; International Vaccine Institute, Seoul, Republic of Korea.
  • Kotloff KL; University of Maryland School of Medicine, Baltimore, MD USA.
  • Koup RA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • McElrath MJ; Fred Hutchinson Cancer Research Center, Seattle, WA USA.
  • Read SW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • Robb ML; Walter Reed Army Institute of Research, Silver Spring, MD USA.
  • Renzullo PO; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
  • D'Souza MP; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
Commun Med (Lond) ; 2: 110, 2022.
Article en En | MEDLINE | ID: mdl-36045906
The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2022 Tipo del documento: Article